Immunomodulatory drugs (IMids), such as thalidomide and lenalidomide, are used to treat plasma cell neoplasms and B-cell malignancies. We present a case of severe direct hyperbilirubinemia in a patient taking lenalidomide-based therapy for plasmacytoma. Imaging was unrevealing, and liver biopsy showed only mild sinusoidal dilation. Roussel Uclaf Causality Assessment (RUCAM) score was 6, indicating lenalidomide was a probable cause of the injury. To our knowledge, this is the highest reported direct bilirubin regarding lenalidomide drug-induced liver injury (DILI), with a peak bilirubin of 41mg/dL. While a clear pathophysiology was not identified, this case provides important considerations regarding lenalidomide safety.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977541 | PMC |
| http://dx.doi.org/10.7759/cureus.34408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Lenalidomide-Associated Hyperbilirubinemia.
Cureus
January 2023
Hematology and Oncology, MedStar Georgetown University Hospital, Washington, D.C., USA.
Immunomodulatory drugs (IMids), such as thalidomide and lenalidomide, are used to treat plasma cell neoplasms and B-cell malignancies. We present a case of severe direct hyperbilirubinemia in a patient taking lenalidomide-based therapy for plasmacytoma. Imaging was unrevealing, and liver biopsy showed only mild sinusoidal dilation.
View Article and Find Full Text PDFLenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis.
Cureus
April 2021
Hematology and Oncology, Brooke Army Medical Center, San Antonio, USA.
Hemophagocytic lymphohistiocytosis (HLH) is a severe systemic inflammatory syndrome that is often fatal. In the adult population, it is believed to develop secondary to immune dysregulation due to rheumatologic, infectious, malignant, and recently, immunomodulatory drugs. It's co-occurrence with phagocytosis by non-macrophage cells has not been previously well defined.
View Article and Find Full Text PDFFludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Leuk Lymphoma
July 2017
a Department of Cellular Biotechnologies and Hematology, Hematology , Sapienza University, Rome , Italy.
The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given at the starting dose of 2.5 mg during course 1.
View Article and Find Full Text PDFClinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Ann Oncol
July 2016
Division of Hematology and Medical Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA.
Lenalidomide is an oral immunomodulatory drug with significant activity in indolent B-cell and mantle cell lymphomas. Lenalidomide has a manageable safety profile whether administered as a single agent or in combination with rituximab. The combination of lenalidomide with rituximab, known as the 'R(2)' regimen, enhances efficacy over what has been shown with monotherapy and has demonstrated activity in patients considered resistant to rituximab.
View Article and Find Full Text PDFOutcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Leuk Lymphoma
November 2016
a Hematology and Oncology, Multiple Myeloma Program , Icahn School of Medicine at Mount Sinai, New York , NY , USA ;
The immunomodulatory drugs thalidomide, lenalidomide, and pomalidomide (IMiDs) are an important component of myeloma treatment; one of six available drug classes for this incurable disease. Rash is a frequent side effect of IMiDs, particularly lenalidomide, often leading to treatment discontinuation. We retrospectively reviewed 52 patients (7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!